Teva Gets Exclusivity For Generic Kytril; FDA Still Worries About Racing, Parking

In granting Teva 180-day marketing exclusivity for its generic formulation of Roche's antinausea drug Kytril (granisetron), FDA has laid out initial ground rules for determining when ANDA holders forfeit exclusivity